Comprehensive Stock Comparison
Compare Ligand Pharmaceuticals Incorporated (LGND) vs BiomX Inc. (PHGE) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety |  LGND | Beta 0.82 vs PHGE's 0.93, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | LGND | +81.1% vs PHGE's -48.8% |
| Efficiency (ROA) | LGND | 3.3% ROA vs PHGE's -142.8%, ROIC -2.3% vs -305.2% |
Who Each Stock Is For
Income & stability
LGNDDividend streak 1 yrs, beta 0.82
Growth exposure
PHGEEPS growth 71.2%
Long-term compounding (10Y)
LGND104.3% 10Y total return vs PHGE's -99.7%
Sleep-well-at-night portfolio
LGNDLower volatility, beta 0.82, Low D/E 0.9%, current ratio 8.93x
Defensive / Recession hedge
LGNDBeta 0.82, current ratio 8.93x
Business Model
What each company does and how it makes money
Ligand Pharmaceuticals is a biopharmaceutical company that develops and acquires drug discovery technologies and royalty-bearing assets for pharmaceutical partners. It generates revenue primarily through royalties from partnered drug sales — including blockbusters like Kyprolis and Veklury — supplemented by milestone payments and contract research services. Its key competitive advantage lies in its diversified portfolio of royalty streams and its Captisol drug formulation technology, which creates multiple revenue sources from single platform innovations.
BiomX is a clinical-stage biotechnology company developing targeted phage therapies — viruses that kill specific harmful bacteria — for chronic diseases and skin conditions. It generates no commercial revenue yet but is funded through equity offerings and partnerships to advance its pipeline, which includes therapies for cystic fibrosis, inflammatory bowel diseases, and atopic dermatitis. The company's key advantage is its proprietary platform for discovering and engineering natural phages that precisely target disease-causing bacteria while sparing beneficial microbes.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
LGND 5PHGE 0LGND1/1 metricsLGND2/2 metricsLGND9/9 metricsLGND5/6 metricsLGND2/2 metricsLGND leads in 5 of 6 categories — strongest in Financial Metrics and Valuation Metrics.
Financial Metrics (TTM)
LGND and PHGE operate at a comparable scale, with $251M and $0 in trailing revenue.
| Metric | LGNDLigand Pharmaceut… | PHGEBiomX Inc. |
|---|---|---|
| RevenueTrailing 12 months | $251M | $0 |
| EBITDAEarnings before interest/tax | $52M | -$6M |
| Net IncomeAfter-tax profit | $49M | -$37M |
| Free Cash FlowCash after capex | $31M | -$28M |
| Gross MarginGross profit ÷ Revenue | +85.9% | — |
| Operating MarginEBIT ÷ Revenue | +7.0% | — |
| Net MarginNet income ÷ Revenue | +19.3% | — |
| FCF MarginFCF ÷ Revenue | +12.2% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +122.8% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +15.6% | -6.5% |
Valuation Metrics
| Metric | LGNDLigand Pharmaceut… | PHGEBiomX Inc. |
|---|---|---|
| Market CapShares × price | $4.1B | $82.8B |
| Enterprise ValueMkt cap + debt − cash | $4.0B | $82.8B |
| Trailing P/EPrice ÷ TTM EPS | -949.77x | -4.29x |
| Forward P/EPrice ÷ next-FY EPS est. | 24.61x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 319.95x | — |
| Price / SalesMarket cap ÷ Revenue | 24.57x | — |
| Price / BookPrice ÷ Book value/share | 4.60x | 3427.64x |
| Price / FCFMarket cap ÷ FCF | 53.06x | — |
Profitability & Efficiency
LGND delivers a 5.1% return on equity — every $100 of shareholder capital generates $5 in annual profit, vs $-4 for PHGE. LGND carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to PHGE's 0.40x. On the Piotroski fundamental quality scale (0–9), LGND scores 5/9 vs PHGE's 3/9, reflecting solid financial health.
| Metric | LGNDLigand Pharmaceut… | PHGEBiomX Inc. |
|---|---|---|
| ROE (TTM)Return on equity | +5.1% | -3.6% |
| ROA (TTM)Return on assets | +3.3% | -142.8% |
| ROICReturn on invested capital | -2.3% | -3.1% |
| ROCEReturn on capital employed | -2.7% | -159.9% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 3 |
| Debt / EquityFinancial leverage | 0.01x | 0.40x |
| Net DebtTotal debt minus cash | -$65M | -$8M |
| Cash & Equiv.Liquid assets | $72M | $18M |
| Total DebtShort + long-term debt | $7M | $10M |
| Interest CoverageEBIT ÷ Interest expense | 22.69x | -36.86x |
Total Returns (with DRIP)
A $10,000 investment in LGND five years ago would be worth $14,470 today (with dividends reinvested), compared to $47 for PHGE. Over the past 12 months, LGND leads with a +81.1% total return vs PHGE's -48.8%. The 3-year compound annual growth rate (CAGR) favors LGND at 43.0% vs PHGE's -59.1% — a key indicator of consistent wealth creation.
| Metric | LGNDLigand Pharmaceut… | PHGEBiomX Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +9.9% | +194.4% |
| 1-Year ReturnPast 12 months | +81.1% | -48.8% |
| 3-Year ReturnCumulative with dividends | +192.2% | -93.2% |
| 5-Year ReturnCumulative with dividends | +44.7% | -99.5% |
| 10-Year ReturnCumulative with dividends | +104.3% | -99.7% |
| CAGR (3Y)Annualised 3-year return | +43.0% | -59.1% |
Risk & Volatility
LGND is the less volatile stock with a 0.82 beta — it tends to amplify market swings less than PHGE's 0.93 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LGND currently trades 98.3% from its 52-week high vs PHGE's 42.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | LGNDLigand Pharmaceut… | PHGEBiomX Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.82x | 0.93x |
| 52-Week HighHighest price in past year | $212.49 | $14.71 |
| 52-Week LowLowest price in past year | $93.58 | $1.56 |
| % of 52W HighCurrent price vs 52-week peak | +98.3% | +42.8% |
| RSI (14)Momentum oscillator 0–100 | 64.3 | 51.0 |
| Avg Volume (50D)Average daily shares traded | 198K | 1.3M |
Analyst Outlook
| Metric | LGNDLigand Pharmaceut… | PHGEBiomX Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $248.00 | — |
| # AnalystsCovering analysts | 16 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Mar 26 | Change |
|---|---|---|---|
| Ligand Pharmaceutic… (LGND) | 100 | 189.96 | +90.0% |
| BiomX Inc. (PHGE) | 100 | 0.23 | -99.8% |
Ligand Pharmaceutic… (LGND) returned +45% over 5 years vs BiomX Inc. (PHGE)'s -100%. A $10,000 investment in LGND 5 years ago would be worth $14,470 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Ligand Pharmaceutic… (LGND) | $72M | $167M | +132.4% |
| BiomX Inc. (PHGE) | $0.00 | $0.00 | — |
Ligand Pharmaceuticals Incorporated's revenue grew from $72M (2015) to $167M (2024) — a 9.8% CAGR.
Chart 3P/E Ratio History — 5 Years
| Stock | 2017 | 2023 | Change |
|---|---|---|---|
| Ligand Pharmaceutic… (LGND) | 258.4 | 24.3 | -90.6% |
Ligand Pharmaceuticals Incorporated has traded in a 3x–258x P/E range over 5 years; current trailing P/E is ~-950x.
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Ligand Pharmaceutic… (LGND) | 12.12 | -0.22 | -101.8% |
| BiomX Inc. (PHGE) | -3.27 | -1.47 | +55.0% |
Ligand Pharmaceuticals Incorporated's EPS grew from $12.12 (2015) to $-0.22 (2024) — a NaN% CAGR.
Chart 5Free Cash Flow — 5 Years
Ligand Pharmaceuticals Incorporated generated $77M FCF in 2024 (+11% vs 2021). BiomX Inc. generated $-37M FCF in 2024 (-18% vs 2021).
LGND vs PHGE: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is LGND or PHGE a better buy right now?
Analysts rate Ligand Pharmaceuticals Incorporated (LGND) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — LGND or PHGE?
Over the past 5 years, Ligand Pharmaceuticals Incorporated (LGND) delivered a total return of +44.7%, compared to -99.5% for BiomX Inc. (PHGE). A $10,000 investment in LGND five years ago would be worth approximately $14K today (assuming dividends reinvested). Over 10 years, the gap is even starker: LGND returned +104.3% versus PHGE's -99.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — LGND or PHGE?
By beta (market sensitivity over 5 years), Ligand Pharmaceuticals Incorporated (LGND) is the lower-risk stock at 0.82β versus BiomX Inc.'s 0.93β — meaning PHGE is approximately 13% more volatile than LGND relative to the S&P 500. On balance sheet safety, Ligand Pharmaceuticals Incorporated (LGND) carries a lower debt/equity ratio of 1% versus 40% for BiomX Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — LGND or PHGE?
BiomX Inc. (PHGE) is the more profitable company, earning 0.0% net margin versus -2.4% for Ligand Pharmaceuticals Incorporated — meaning it keeps 0.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PHGE leads at 0.0% versus -13.5% for LGND. At the gross margin level — before operating expenses — LGND leads at 93.4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — LGND or PHGE?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is LGND or PHGE better for a retirement portfolio?
For long-horizon retirement investors, Ligand Pharmaceuticals Incorporated (LGND) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.82), +104.3% 10Y return). Both have compounded well over 10 years (LGND: +104.3%, PHGE: -99.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between LGND and PHGE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.